The Chinese ketoprofen API market has seen a steep stabilisation of price trends in the recent months, indicating a multifaceted balance between strong pharma sector demand and shifting supply-side factors. As a prominent non-steroidal anti-inflammatory drug (NSAID) active, ketoprofen API continues to be in constant demand from local and offshore formulators, fueled by growing healthcare demands and increasing generic drug manufacturing. On the supply side, producers have learned to cope with feedstock volatility and pressure on production costs while maintaining ongoing production to serve local and export markets. The interaction among policy regulation, international flows of trade, and energy price volatility further conditions the market environment, pointing the way toward cautious optimism in the short term.
Key Highlights
-
Ketoprofen API demand remains buoyant, fueled by China’s burgeoning generic drug industry and increasing over-the-counter (OTC) pain management formulations.
-
Chinese producers continue to capitalize on strong export demand, particularly to Southeast Asia and Latin America, as global formulators seek cost-effective API solutions.
-
Recent policy support for domestic API production and export incentives has bolstered market confidence, encouraging capacity expansions.
-
Despite intermittent feedstock price volatility, ketoprofen API producers have maintained stable inventories, ensuring consistent supply to key markets.
Chinese ketoprofen API is dominated by the pharma sector, where the drug is a key material for anti-inflammatory and painkillers. During August to October, the price of ketoprofen API increased from USD xx,xxx/MT to USD xx,xxx/MT, representing a percentage increase of around x.xxx. Local demand has been triggered by increased healthcare infrastructure within the country and the preference for low-cost generic drugs. OTC analgesic sales on the retail level, generally in the...
